Pages that link to "Q43636858"
Jump to navigation
Jump to search
The following pages link to Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis (Q43636858):
Displaying 50 items.
- Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis (Q24186760) (← links)
- Aminoglycosides and other nonsense suppression therapies for the treatment of dystrophinopathy (Q24240721) (← links)
- New developments in aminoglycoside therapy and ototoxicity (Q24599985) (← links)
- New and emerging targeted therapies for cystic fibrosis (Q26749278) (← links)
- Translational readthrough potential of natural termination codons in eucaryotes--The impact of RNA sequence (Q26801496) (← links)
- Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives (Q28073063) (← links)
- Novel small molecules potentiate premature termination codon readthrough by aminoglycosides (Q28828711) (← links)
- Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy. (Q30350675) (← links)
- Intracellular mechanisms of aminoglycoside-induced cytotoxicity. (Q30454411) (← links)
- In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study (Q33280494) (← links)
- Aminoglycosides, but not PTC124 (Ataluren), rescue nonsense mutations in the leptin receptor and in luciferase reporter genes (Q33681878) (← links)
- Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor (Q33799590) (← links)
- Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers (Q34003192) (← links)
- PTC124 targets genetic disorders caused by nonsense mutations (Q34003720) (← links)
- Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis (Q34023921) (← links)
- Targets for cystic fibrosis therapy: proteomic analysis and correction of mutant cystic fibrosis transmembrane conductance regulator (Q34082569) (← links)
- Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial (Q34132007) (← links)
- Gentamicin-Induced Correction of CFTR Function in Patients with Cystic Fibrosis andCFTRStop Mutations (Q34268532) (← links)
- Class 1 CF Mutations (Q34283509) (← links)
- Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients (Q34297656) (← links)
- Translational read-through of the RP2 Arg120stop mutation in patient iPSC-derived retinal pigment epithelium cells. (Q34442266) (← links)
- Gentamicin in pharmacogenetic approach to treatment of cystic fibrosis (Q34469942) (← links)
- Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis. (Q34549637) (← links)
- Pediatrics, surfactant, and cystic fibrosis in AJRCCM 2001. (Q34550140) (← links)
- Towards the pharmacogenomics of cystic fibrosis. (Q34609152) (← links)
- Nonsense-mediated decay in genetic disease: friend or foe? (Q34658988) (← links)
- Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model (Q34663623) (← links)
- PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model (Q34749864) (← links)
- A new series of small molecular weight compounds induce read through of all three types of nonsense mutations in the ATM gene (Q34775214) (← links)
- Making sense of nonsense GABA(A) receptor mutations associated with genetic epilepsies (Q34789999) (← links)
- Gentamicin as gene therapy (Q34844964) (← links)
- Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation (Q34901567) (← links)
- Nonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutations (Q35105699) (← links)
- The phenotypic consequences of CFTR mutations (Q35206694) (← links)
- Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases (Q35287888) (← links)
- Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54 (Q35482151) (← links)
- Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis (Q35557791) (← links)
- Emerging drug treatments for cystic fibrosis (Q35602683) (← links)
- Cystic fibrosis in adults: current and future management strategies (Q35625683) (← links)
- Pharmacological approaches to correcting the ion transport defect in cystic fibrosis (Q35627639) (← links)
- Home management of haemophilia. (Q35666730) (← links)
- Nonsense-mediated decay approaches the clinic (Q35851264) (← links)
- No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations (Q35855342) (← links)
- Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment (Q36114460) (← links)
- Suppression of premature termination codons as a therapeutic approach. (Q36203719) (← links)
- Understanding drug ototoxicity: molecular insights for prevention and clinical management (Q36446895) (← links)
- Targeted therapy for cystic fibrosis: cystic fibrosis transmembrane conductance regulator mutation-specific pharmacologic strategies (Q36615230) (← links)
- Aminoglycoside-induced translational read-through in disease: overcoming nonsense mutations by pharmacogenetic therapy (Q36691067) (← links)
- Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials (Q36891541) (← links)
- Moderate intensity exercise mediates comparable increases in exhaled chloride as albuterol in individuals with cystic fibrosis (Q37087501) (← links)